The U.S. Supreme Court said it will rule in a case involving payments by pharmaceutical companies to rivals in return for delaying sales of generic drugs.
The Federal Trade Commission says the so-called pay-for-delay deals violate antitrust law, preserve monopolies and artificially jack up prices, the Los Angeles Times said Saturday.
The commission said 28 such agreements cost consumers and taxpayers at least $3.5 billion in 2011, the newspaper reported.
"When drug companies agree not to compete, consumers lose," FTC Chairman Jon Leibowitz said.
Federal courts have upheld such deals in a number of cases, finding they constitute settlements of patent disputes.
The Supreme Court said Friday it would consider a case involving an agreement in which Solvay Pharmaceuticals Inc., which makes the testosterone booster AndroGel, agreed to pay Watson Pharmaceuticals Inc. more than $19 million a year in return for Watson's agreement to hold a competitive drug off the market until 2015.
Most Popular Stories
- National Retail Federation Reduces Sales Forecast
- Desktop, Laptop Setups Still King
- Execs Help Entrepreneurs, Get Chevy Volts
- Demand for Fair Trade Brings Big Opportunity, Clear Conscience
- Shania Twain's Vegas residency ending after 110 shows
- Zillow in Reported $2B Bid for Real Estate Rival Trulia
- Google Confirms $1B Acquisition of Twitch.tv
- Sporty Ford Fiesta Fires on All 3 Cylinders
- Honda' s Accord Plug-in Hybrid Is a Fuel Miser
- Amazon Hiring on Calif.'s Central Coast